【摘要】目的探讨腹膜透析(peritoneal dialysis，PD)患者骨量异常的影响因素及与远期预后的关系。方法采用双能X 线法测定PD 患者骨密度，同时采集其临床、生化检验结果。记录患者骨折、死亡的时间及原因。分析PD 患者骨密度的影响因素及其与全因死亡和心血管死亡的关系。结果共74 例PD 患者纳入研究，女性38 人，平均年龄(60.9±14.1)岁，中位随访时间59.5(27.8,98.0)个月，随访期间共52 人死亡，其中26 人为心血管死亡，5 人骨折。腰椎与股骨骨量异常的诊断率存在统计学差异(χ2=17.697，P＜0.001)。低体质量指数(OR=0.666，95% CI：0.508～0.874，P=0.003)和高龄(OR=1.065，95% CI：1.007～1.126，P=0.027)是股骨骨量异常的独立危险因素。多因素COX 回归分析显示：股骨骨量异常使PD 患者心血管死亡风险增加2.58 倍(HR=3.582，95% CI：1.193～10.760，P=0.023)。结论股骨骨量异常是PD 患者心血管死亡风险的独立预测因素。
王伊娜
,
燕宇
,
赵慧萍
,
武蓓
,
芦丽霞
,
乔婕
,
门春翠
,
何玉婷
,
楚新新
,
王梅
. 腹膜透析患者骨量异常与远期预后的关系[J]. 中国血液净化, 2022
, 21(03)
: 167
-171
.
DOI: 10.3969/j.issn.1671-4091.2022.03.006
【Abstract】Objective To investigate the determinant factors for abnormal bone mass and the relationship between abnormal bone mass and long- term outcomes in peritoneal dialysis (PD) patients. Methods Bone mineral density was assessed by dual-energy x-ray absorptiometry. Clinical data and laboratory indices of the PD patients were collected. The time and cause of fracture or death were documented. The determinant factors of bone density and the relationship between bone density and all-cause mortality and cardiovascular mortality were analyzed in the PD patients. Results A total of 74 PD (average age 60.9±14.1 years old, 38 females) patients were enrolled in the study, with a median follow-up period of 59.5 (27.8, 98.0) months. During the follow-up period, 52 patients died, of which 26 died of cardiovascular events, and 5 had fractures. The rate of abnormal bone mass diagnosed by lumbar spine examination and that by femur examination were significant different (χ2=17.697, P＜0.001). Low BMI (OR=0.666, 95% CI 0.508～0.874, P=0.003) and advanced age (OR=1.065, 95% CI 1.007～1.126, P=0.027) were the independent risk factors for femoral abnormal bone mass. Multivariate COX regression analysis revealed that abnormal femoral bone mass increased the risk of cardiovascular mortality for 2.58 times (HR=3.582, 95% CI 1.193～10.760, P=0.023). Conclusion
Abnormal femoral bone mass is an independent predictor for the risk of cardiovascular mortality in PD patients.
[1]Kidney Disease: Improving Global Outcomes CKDMBDUWG.KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis,Evaluation,Prevention,and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD)[J].Kidney Int Suppl, 2017, 7(1):1-59
[2]Assessment of fracture risk and its application to screening for postmenopausal osteoporosis.Report of a WHO Study Group[J]. World Health Organ Tech Rep Ser, 1994, 843: 1-129. doi:
[3]甘良英, 王梅, 于小勇.线平片在诊断血液透析患者血管钙化中的应用[J].中华肾脏病杂志, 2009, 25(2):5-8
[4]Ersoy FF, Passadakis SP, Tam P, et al.Bone mineral density and its correlation with clinical and laboratory factors in chronic peritoneal dialysis patients[J].J Bone Miner Metab, 2006, 24(1):79-86
[5]Ott SM.Review article: Bone density in patients with chronic kidney disease stages 4-5[J].Nephrology (Carlton), 2009, 14(4):395-403
[6]Niu Q, Hong Y, Lee CH, et al.Abdominal aortic calcification can predict all-cause mortality and CV events in dialysis patients: A systematic review and meta-analysis[J].PLoS One, 2018, 13(9):e0204526-
[7]Bristow SM, Gamble GD, Horne AM, et al.Longitudinal changes in bone mineral density, bone mineral content and bone area at the lumbar spine and hip in postmenopausal women, and the influence of abdominal aortic calcification[J]. Bone Rep, 2019, 10: 100190. doi: 10.1016/j.bonr.2018.100190
[8]Grzegorzewska AE, Mlot-Michalska M.Bone mineral density, its predictors, and outcomes in peritoneal dialysis patients[J]. Adv Perit Dial, 2011, 27: 140-145. doi:
[9]Ersoy FF.Osteoporosis in the elderly with chronic kidney disease[J].Int Urol Nephrol, 2007, 39(1):321-331
[10]Chen Z, Qureshi AR, Ripsweden J, et al.Vertebral bone density associates with coronary artery calcification and is an independent predictor of poor outcome in end-stage renal disease patients[J]. Bone, 2016, 92: 50-57. doi: 10.1016/j.bone.2016.08.007
[11]Toussaint ND, Lau KK, Strauss BJ, et al.Associations between vascular calcification,arterial stiffness and bone mineral density in chronic kidney disease[J].Nephrol Dial Transplant, 2008, 23(2):586-593
[12]Claes KJ, Viaene L, Heye S, et al.Sclerostin: Another vascular calcification inhibitor?[J].J Clin Endocrinol Metab, 2013, 98(8):3221-3228
[13]Mace ML, Gravesen E, Nordholm A, et al.Chronic Kidney Disease-Induced Vascular Calcification Impairs Bone Metabolism[J].J Bone Miner Res, 2021, 36(3):510-522
[14]Leow K, Szulc P, Schousboe JT, et al.Prognostic Value of Abdominal Aortic Calcification: A Systematic Review and Meta-Analysis of Observational Studies[J].J Am Heart Assoc, 2021, 10(2):e017205-
[15]Rodondi N, Taylor BC, Bauer DC, et al.Association between aortic calcification and total and cardiovascular mortality in older women[J].J Intern Med, 2007, 261(3):238-244
[16]Paccou J, Edwards MH, Ward KA, et al.Ischemic heart disease is associated with lower cortical volumetric bone mineral density of distal radius[J].Osteoporos Int, 2015, 26(7):1893-1901
[17]Laroche M.Intraosseous circulation from physiology to disease[J].Joint Bone Spine, 2002, 69(3):262-269
[18]Zotos P.Bone Metabolism in Chronic Heart Failure[J]. Journal of Osteoporosis & Physical Activity, 2014, 02(2). doi:
[19]Loncar G, Cvetinovic N, Lainscak M, et al.Bone in heart failure[J].J Cachexia Sarcopenia Muscle, 2020, 11(2):381-393
[20]Naylor KL, Garg AX, Zou G, et al.Comparison of fracture risk prediction among individuals with reduced and normal kidney function[J].Clin J Am Soc Nephrol, 2015, 10(4):646-653
[21]Jamal SA, West SL, Miller PD.Fracture risk assessment in patients with chronic kidney disease[J].Osteoporos Int, 2012, 23(4):1191-1198
[22]Sprague SM, Bellorin-Font E, Jorgetti V, et al.Diagnostic Accuracy of Bone Turnover Markers and Bone Histology in Patients With CKD Treated by Dialysis[J].Am J Kidney Dis, 2016, 67(4):559-566
